BEVERLY HILLS, Calif.– GordonMD Global Investments® announced its participation in an oversubscribed $125 million Series D financing round for Star Therapeutics, a clinical-stage biotechnology company focused on developing novel antibody therapies for bleeding disorders and other serious diseases. GordonMD Global Investments® joins as a new investor, reaffirming the firm’s commitment to advancing groundbreaking innovations in hematology.
The Series D round was co-led by Sanofi Ventures and Viking Global Investors, with participation from Janus Henderson Investors, Frazier Life Sciences, and other existing backers. The funding will accelerate the clinical development of Star Therapeutics’ lead candidate, VGA039 — a pioneering antibody that targets Protein S to restore balance in blood clotting. VGA039 is being developed as a universal therapy for bleeding disorders, beginning with von Willebrand Disease (VWD), and has entered a pivotal Phase 3 clinical trial in VWD patients.
“We are pleased to support Star Therapeutics as it advances VGA039 into late-stage clinical development,” said Dr. Craig Gordon, Founder and Chief Executive Officer of GordonMD Global Investments®. “Star’s innovative approach has the potential to change the standard of care for patients with serious bleeding disorders.”
Adam Rosenthal, Ph.D., CEO and Founder of Star Therapeutics, welcomed the new partnership, noting, “The addition of GordonMD Global Investments® to our strong syndicate of life sciences investors reinforces the significance of our work and the broad enthusiasm for VGA039. This investment will help us continue to progress our pipeline as we work to deliver meaningful advances for patients with bleeding disorders.”
The new funding will support Star Therapeutics’ continued mission to develop transformative antibody-based therapies that address unmet medical needs in hematology and beyond.
